Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (NCT05243797)
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Who can join: Review the eligibility criteria below.
Location: Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (212 Sites)
Showing the first 25 of 212 sites.
- Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
- UCLA Medical Center — Los Angeles, California
- University of California-Davis Cancer Center — Sacramento, California
- University of California, San Diego (UCSD) Medical Center — San Diego, California
- University of Colorado Hospital — Aurora, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Yale New Haven Hospital — New Haven, Connecticut
- Christiana Care — Newark, Delaware
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group — Orlando, Florida
- Moffitt at Memorial Healthcare System — Tampa, Florida
- Emory University Hospital — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- University of Illinois Medical Center at Chicago — Chicago, Illinois
- Greenebaum Cancer Center UM of MD — Baltimore, Maryland
- John Hopkins — Baltimore, Maryland
- Tufts Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Henry Ford St. John Hospital — Grosse Pointe Woods, Michigan
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- Mount Sinai Medical Center - 2 — New York, New York
- Montefiore Medical Cente — The Bronx, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Duke University — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
📞 Contact the Study Coordinator
Phone: +31 10 268 70 65
Email: Christine.Witty@emn.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.